543 related articles for article (PubMed ID: 20438581)
1. Pharmacological therapy in Parkinson's disease: focus on neuroprotection.
Kincses ZT; Vecsei L
CNS Neurosci Ther; 2011 Oct; 17(5):345-67. PubMed ID: 20438581
[TBL] [Abstract][Full Text] [Related]
2. New hopes for disease modification in Parkinson's Disease.
Poewe W; Seppi K; Marini K; Mahlknecht P
Neuropharmacology; 2020 Jul; 171():108085. PubMed ID: 32298705
[TBL] [Abstract][Full Text] [Related]
3. Rifampicin and Parkinson's disease.
Bi W; Zhu L; Jing X; Liang Y; Tao E
Neurol Sci; 2013 Feb; 34(2):137-41. PubMed ID: 22821065
[TBL] [Abstract][Full Text] [Related]
4. Antiparkinsonian drugs and their neuroprotective effects.
Kitamura Y; Kakimura J; Taniguchi T
Biol Pharm Bull; 2002 Mar; 25(3):284-90. PubMed ID: 11913520
[TBL] [Abstract][Full Text] [Related]
5. Ghrelin mediated neuroprotection - A possible therapy for Parkinson's disease?
Morgan AH; Rees DJ; Andrews ZB; Davies JS
Neuropharmacology; 2018 Jul; 136(Pt B):317-326. PubMed ID: 29277488
[TBL] [Abstract][Full Text] [Related]
6. Targets for neuroprotection in Parkinson's disease.
Yacoubian TA; Standaert DG
Biochim Biophys Acta; 2009 Jul; 1792(7):676-87. PubMed ID: 18930814
[TBL] [Abstract][Full Text] [Related]
7. Free-radical toxicity and antioxidant medications in Parkinson's disease.
Ciccone CD
Phys Ther; 1998 Mar; 78(3):313-9. PubMed ID: 9520976
[No Abstract] [Full Text] [Related]
8. Evaluation of the neuroprotective potential of caffeic acid phenethyl ester in a cellular model of Parkinson's disease.
Turan D; Abdik H; Sahin F; Avşar Abdik E
Eur J Pharmacol; 2020 Sep; 883():173342. PubMed ID: 32634439
[TBL] [Abstract][Full Text] [Related]
9. Possible neuroprotective therapy for Parkinson's disease.
Ogawa N
Acta Med Okayama; 1995 Aug; 49(4):179-85. PubMed ID: 7502677
[TBL] [Abstract][Full Text] [Related]
10. Renin-angiotensin system as a potential target for new therapeutic approaches in Parkinson's disease.
Perez-Lloret S; Otero-Losada M; Toblli JE; Capani F
Expert Opin Investig Drugs; 2017 Oct; 26(10):1163-1173. PubMed ID: 28836869
[TBL] [Abstract][Full Text] [Related]
11. Disease-Modifying Drugs in Parkinson's Disease.
Park A; Stacy M
Drugs; 2015 Dec; 75(18):2065-71. PubMed ID: 26581672
[TBL] [Abstract][Full Text] [Related]
12. Peroxisome Proliferator Activated Receptor Gamma Coactivator 1 Alpha: An Emerging Target for Neuroprotection in Parkinson's Disease.
Das NR; Sharma SS
CNS Neurol Disord Drug Targets; 2015; 14(8):1024-30. PubMed ID: 25808897
[TBL] [Abstract][Full Text] [Related]
13. Lutein protects dopaminergic neurons against MPTP-induced apoptotic death and motor dysfunction by ameliorating mitochondrial disruption and oxidative stress.
Nataraj J; Manivasagam T; Thenmozhi AJ; Essa MM
Nutr Neurosci; 2016 Jul; 19(6):237-46. PubMed ID: 25730317
[TBL] [Abstract][Full Text] [Related]
14. Progress in neuroprotection in Parkinson's disease.
Schapira AH
Eur J Neurol; 2008 Apr; 15 Suppl 1():5-13. PubMed ID: 18353131
[TBL] [Abstract][Full Text] [Related]
15. Modulation of endoplasmic reticulum stress in Parkinson's disease.
Tsujii S; Ishisaka M; Hara H
Eur J Pharmacol; 2015 Oct; 765():154-6. PubMed ID: 26297973
[TBL] [Abstract][Full Text] [Related]
16. Preclinical evidence for neuroprotection with monoamine oxidase-B inhibitors in Parkinson's disease.
Jenner P
Neurology; 2004 Oct; 63(7 Suppl 2):S13-22. PubMed ID: 15477581
[No Abstract] [Full Text] [Related]
17. Clinical aspects of neuroprotection in Parkinson's disease.
Przuntek H
J Neural Transm Suppl; 1994; 43():163-9. PubMed ID: 7884398
[TBL] [Abstract][Full Text] [Related]
18. [Neuroprotection in Parkinson's disease: analysis though group of experts' methodology].
Linazasoro G; Sesar A; Valldeoriola F; Compta Y; Herrero MT; Martínez Castrillo JC; López Lozano JJ; Bergaretxe A; Vela L; Fernández JM; Castro A; Kulisevski J; Lezcano E; Vaamonde J; López Del Val J; Chacón J; Vivancos F; Luquin R; Aguilar M; Burguera JA; Salvador C; Menéndez Guisasola L; Catalán MJ; Mir P; Campos V; Grandas F; Mínguez A; Balaguer E; Yáñez R; Leiva C; García Ruiz P; Cubo E
Neurologia; 2009 Mar; 24(2):113-24. PubMed ID: 19322690
[TBL] [Abstract][Full Text] [Related]
19. Potential neuroprotection mechanisms in PD: focus on dopamine agonist pramipexole.
Albrecht S; Buerger E
Curr Med Res Opin; 2009 Dec; 25(12):2977-87. PubMed ID: 19842998
[TBL] [Abstract][Full Text] [Related]
20. Rational drug discovery design approaches for treating Parkinson's disease.
Van der Schyf CJ
Expert Opin Drug Discov; 2015 Jul; 10(7):713-41. PubMed ID: 26054694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
